GPR84 receptor antagonist and use thereof

Patent metadata

Field	Value
Publication number	US-11098071-B2
Application number	US-201816490837-A
Country	US
Kind code	B2
Filing date	Feb 28, 2018
Priority date	Mar 6, 2017
Publication date	Aug 24, 2021
Grant date	Aug 24, 2021

Abstract

The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.

First claim

The invention claimed is:

1. A compound or a pharmaceutically acceptable salt having the structure of formula I,

wherein,
Y is O or S;
Z is H, or an ion of the following metal: L 1 , Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or a conjugated acid of the following base: NH 3 , arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, aminoglucose, histidine, hydroxycobalamin, isopropylamine, lysine, methyl glucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, trometamol;
L 3 and L 6 are each O;
each of rings A, B, C, and D is independently a benzene ring or a thiophene ring;
R 1 , R 2 , R 3 , and R 4 are each independently 1 to 4 substituents on rings A, B, C, and D, and each substituent is independently absent, hydroxyl, mercapto, amino, F, Cl, Br, I, —C r H 2r -L 7 -C s H 2s+1 , —C r H 2r —N(C t H 2t+1 )—C s H 2s+1 , substituted or unsubstituted C 1 -C 6 alkyl, the above substitution means there is one or more substituents selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxyl, amino, —COOC 1 -C 6 alkyl, —COOH; L 7 is each independently O, S, NH, each r is independently an integer of 0-6, each s is independently an integer of 0-6, and each t is independently an integer of 1-6;
L 2 and L 5 are each independently absent or CH;
L 1 and L 4 are each independently absent, CH, O, S, SO, SO 2 , —CH═CH—, CO, —C(═CH 2 )—, substituted or unsubstituted C 1 -C 6 alkylidene, —NH—, —N(C 1 -C 4 alkyl)-, said “substituted” means that there is one or more substituents selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy;
represents a single bond or a double bond.

2. The compound according to claim 1 , wherein R 1 , R 2 , R 3 and R 4 are each independently one, two or three substituents on rings A, B, C and D, and each substituent is independently absent, substituted or unsubstituted C 1 -C 4 alkyl, —C r H 2r -L 7 -C s H 2s+1 , —C r H 2r —N(C t H 2t+1 )—C s H 2s+1 , hydroxyl, mercapto, amino, F, Cl, Br, I; the above substitution means there is one or more substituents selected from the group consisting of halogen, hydroxyl, amino, —COOC 1 -C 6 alkyl, —COOH; L 7 is each independently O, S, NH, each r is independently an integer of 0-4, each s is independently an integer of 0-4, and each t is independently an integer of 1-4.

3. The compound according to claim 1 , wherein L 1 and L 4 are each independently absent, CH, O, S, SO, SO 2 , —CH═CH—, CO, —C(═CH 2 )—, substituted or unsubstituted C 1 -C 4 alkylidene, —NH—, —N(C 1 -C 3 alkyl)-, C 3 -C 6 cycloalkyl or C 3 -C 6 oxa-cycloalkyl, said substitution means there is one or more substituents selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxyl.

4. The compound according to claim 1 , wherein, a carbon attached to L 3 and/or L 6 and a carbon of ring B and/or ring D form —CH═CH— when L 2 and/or L 5 are absent;
a carbon attached to L 3 and/or L 6 and a carbon attached to L 2 and/or L 5 form —CH═CH when L 2 and/or L 5 are CH.

5. A compound having the following structure

6. A method for preparing the compound according to claim 1 , wherein the method comprises the following step:

reacting a compound of formula S1, a compound of formula S2 and a compound of formula S3 as starting materials to obtain the compound of formula I,
wherein R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , Y, Z, ring A, B, C, and D are as defined in claim 1 , and represents a single bond or a double bond;
X is F, Cl, Br or I.

7. A method for preparing the compound according to claim 1 , wherein the method comprises the following steps:

wherein R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , Y, Z, ring A, B, C, and D are as defined in claim 1 , and represents a single bond or a double bond;
X is F, Cl, Br or I.

8. A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt according to claim 1 ; and
a pharmaceutically acceptable carrier.

9. A method for antagonizing GPR84 comprising administering the compound or the pharmaceutically acceptable salt according to claim 1 to a subject in need thereof.

10. A method for treating a disease caused by hyper-excitability or high expression of GPR84 receptor comprising administering the compound or the pharmaceutically acceptable salt according to claim 1 to a subject in need thereof, wherein the disease is multiple sclerosis, obesity, inflammatory bowel disease or arthritis.

11. The method of claim 10 , wherein the disease is multiple sclerosis, inflammatory bowel disease or arthritis.

Assignees

• Shanghai Inst Materia Medica Cas

Inventors

• Nan Fajun
• Xie Xin
• Chen Linhai
• Zhang Qing
• Xiao Yufeng
• Yang Hui

Classifications

• C07F9/12 Primary

  with hydroxyaryl compounds · CPC title

• C07F9/65539 Primary

  condensed with carbocyclic rings or carbocyclic ring systems · CPC title

• C07F9/5535

  condensed with carbocyclic rings or ring systems · CPC title

• A61K31/6615

  Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid · CPC title

• A61K31/67

  having sulfur as a ring hetero atom · CPC title